Background:

Telratolimod is a toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity.

Telratolimod (3M-052) is a toll like receptors 7/8 (TLR7/8) agonist, with antitumor activity[1].

Telratolimod (50 μg) inhibits the tumor volume, and more potently blocks tumor gowth in combination with CpG ODN in BALB/c mice bearing CT26 colon carcinoma cells. Telratolimod (100 μg) plus 200 μg of CpG ODN slows tumor growth and prolongs survival of mice bearing large tumors[1].

[1]. Zhao BG, et al. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12.